Revolution Medicines

We are proud to announce that RevMed’s publication on the discovery of daraxonrasib (RMC-6236), our RAS(ON) multi-selective inhibitor, has been selected as an American Chemical Society’s Editors’ Choice by the Journal of Medicinal Chemistry.   The ACS Editors’ Choice initiative highlights one article each day that is chosen from the entire ACS portfolio. Revolution Medicines' paper has been selected for this honor because of its potential for broad public interest. This distinction is based on recommendations by Editors of ACS's peer-reviewed journals, and selection by a panel of ACS Publications Managing Editors.   In addition to the daraxonrasib Editors’ Choice publication, JMC recently published our paper on the discovery of elironrasib (RMC-6291), our RAS(ON) G12C-selective inhibitor.   Daraxonrasib (RMC-6236): https://lnkd.in/dYUuKwgh Elironrasib (RMC-6291): https://lnkd.in/gKZz2-BQ

Join us on March 19 at 4 PM PT for the National Pancreas Foundation Patient Education Series Webinar, Decoding Pancreatic Cancer: The Role of Testing & Genetics. This important discussion will feature leading experts Dr. Eileen O’Reilly, Dr. Efrat Dotan, and Dr. David Whitcomb, along with a patient speaker and NPF’s 2024 Hero of Hope, sharing insights on how testing and genetics shape treatment decisions. We are proud to sponsor this initiative, reinforcing our commitment to advancing research and supporting patients in their journey. Register now: https://lnkd.in/gBKYTpdr

At Revolution Medicines, our remarkable culture is built on a shared commitment to our core values and principles that guide us in our mission to develop targeted therapies for RAS-addicted cancers. We are proud to recognize a group of outstanding individuals through our Remarkable Awards, honoring those who consistently embody these values in their work. Selected through an organization-wide nomination process and reviewed by senior leadership, these awardees exemplify the dedication, innovation, and teamwork that drive us forward. Congratulations to our Remarkable Award recipients, and a heartfelt thank you to all our Revolutionaries for your commitment to our shared mission.

Pancreatic cancer is one of the deadliest and most challenging cancers to treat, but the landscape is evolving.  The Wall Street Journal recently highlighted exciting progress in RAS-targeting therapies, including Revolution Medicines' investigational drug. While pancreatic cancer is on the rise and has historically been resistant to many treatments, recent breakthroughs are creating new hope for patients.    Read more in WSJ (subscription needed): https://lnkd.in/gyz_Yi9V

Today, we announced our Q4 and full-year 2024 financial results along with key updates on our corporate progress. This year, we remain focused on advancing our pipeline, including enrolling patients in our RASolve 301 trial in non-small cell lung cancer and RASolute 302 trial in pancreatic cancer. Read the full announcement: https://lnkd.in/gf9uRY6t

On World Cancer Day, we honor the patients, caregivers, and clinical investigators who inspire and drive the search for better treatments. Every breakthrough in cancer research is made possible by their resilience, dedication, and participation. At Revolution Medicines, we remain committed to addressing the unmet needs of those affected by RAS-addicted cancers, striving to advance targeted therapies that have the potential to transform outcomes. To everyone impacted by cancer—you are at the heart of our mission. #WorldCancerMonth #WorldCancerDay #PancreaticCancer

Revolution Medicines' CEO and chairman, Mark Goldsmith, will be a featured speaker at the Guggenheim Securities SMID Cap Biotech Conference in New York. Dr. Mark Goldsmith's fireside chat on February 5 at 10:30 a.m. ET will share insights into our work advancing targeted therapies for patients with RAS-addicted cancers. Visit the release for more information on the event and webcast details: https://lnkd.in/g6nXgSQm

Revolution Medicines CEO and Chairman, Mark A. Goldsmith, M.D., Ph.D., will be delivering a corporate presentation at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025, at 10:30 a.m. PT. Watch the live webcast or access the replay on our “Events & Presentations” page here: https://lnkd.in/gdxVeJt Full details: https://lnkd.in/gTN-7F6M

As 2024 comes to a close, we packed our 500+ team into the historic Fox Theatre in Redwood City for an unforgettable-year end event! The event was an inspiring reflection on our journey this year—from groundbreaking advancements in cancer research to hearing first-hand stories from physicians and patients living with RAS-addicted cancers. It was a powerful reminder of the profound purpose behind our work. Here's to an even more impactful 2025!

We’re excited to announce the launch of ExpectRAS.com, to help improve awareness on the prevalence of RAS in patients with pancreatic ductal adenocarcinoma (PDAC)   RAS mutations are the one of the most common mutations. In fact, RAS mutations drive 90% of all PDAC cases.   Revolution Medicines is committed to deepening our understanding of the role of RAS and identifying therapeutic options for patients living with pancreatic cancer. Learn more at ExpectRAS.com #Oncology #PancreaticCancer